Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL study group.
Childhood acute lymphoblastic leukemia
Hepatotoxicity
Hyperbilirubinemia
Treatment-related toxicity
UGT1A
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
13 Jan 2023
13 Jan 2023
Historique:
received:
07
12
2022
accepted:
26
12
2022
entrez:
13
1
2023
pubmed:
14
1
2023
medline:
18
1
2023
Statut:
epublish
Résumé
Characterization of clinical phenotypes in context with tumor and host genomic information can aid in the development of more effective and less toxic risk-adapted and targeted treatment strategies. To analyze the impact of therapy-related hyperbilirubinemia on treatment outcome and to identify contributing genetic risk factors of this well-recognized adverse effect we evaluated serum bilirubin levels in 1547 pediatric patients with acute lymphoblastic leukemia (ALL) and conducted a genome-wide association study (GWAS). Patients were treated in multicenter trial AIEOP-BFM ALL 2000 for pediatric ALL. Bilirubin toxicity was graded 0 to 4 according to the Common Toxicity Criteria (CTC) of the National Cancer Institute. In the GWAS discovery cohort, including 650 of the 1547 individuals, genotype frequencies of 745,895 single nucleotide variants were compared between 435 patients with hyperbilirubinemia (CTC grades 1-4) during induction/consolidation treatment and 215 patients without it (grade 0). Replication analyses included 224 patients from the same trial. Compared to patients with no (grade 0) or moderate hyperbilirubinemia (grades 1-2) during induction/consolidation, patients with grades 3-4 had a poorer 5-year event free survival (76.6 ± 3% versus 87.7 ± 1% for grades 1-2, P = 0.003; 85.2 ± 2% for grade 0, P < 0.001) and a higher cumulative incidence of relapse (15.6 ± 3% versus 9.0 ± 1% for grades 1-2, P = 0.08; 11.1 ± 1% for grade 0, P = 0.007). GWAS identified a strong association of the rs6744284 variant T allele in the UGT1A gene cluster with risk of hyperbilirubinemia (allelic odds ratio (OR) = 2.1, P = 7 × 10 Chemotherapy-related hyperbilirubinemia is a prognostic factor for treatment outcome in pediatric ALL and genetic variation in UGT1A aids in predicting the clinical impact of hyperbilirubinemia. http://www. gov ; #NCT00430118.
Sections du résumé
BACKGROUND
BACKGROUND
Characterization of clinical phenotypes in context with tumor and host genomic information can aid in the development of more effective and less toxic risk-adapted and targeted treatment strategies. To analyze the impact of therapy-related hyperbilirubinemia on treatment outcome and to identify contributing genetic risk factors of this well-recognized adverse effect we evaluated serum bilirubin levels in 1547 pediatric patients with acute lymphoblastic leukemia (ALL) and conducted a genome-wide association study (GWAS).
PATIENTS AND METHODS
METHODS
Patients were treated in multicenter trial AIEOP-BFM ALL 2000 for pediatric ALL. Bilirubin toxicity was graded 0 to 4 according to the Common Toxicity Criteria (CTC) of the National Cancer Institute. In the GWAS discovery cohort, including 650 of the 1547 individuals, genotype frequencies of 745,895 single nucleotide variants were compared between 435 patients with hyperbilirubinemia (CTC grades 1-4) during induction/consolidation treatment and 215 patients without it (grade 0). Replication analyses included 224 patients from the same trial.
RESULTS
RESULTS
Compared to patients with no (grade 0) or moderate hyperbilirubinemia (grades 1-2) during induction/consolidation, patients with grades 3-4 had a poorer 5-year event free survival (76.6 ± 3% versus 87.7 ± 1% for grades 1-2, P = 0.003; 85.2 ± 2% for grade 0, P < 0.001) and a higher cumulative incidence of relapse (15.6 ± 3% versus 9.0 ± 1% for grades 1-2, P = 0.08; 11.1 ± 1% for grade 0, P = 0.007). GWAS identified a strong association of the rs6744284 variant T allele in the UGT1A gene cluster with risk of hyperbilirubinemia (allelic odds ratio (OR) = 2.1, P = 7 × 10
CONCLUSIONS
CONCLUSIONS
Chemotherapy-related hyperbilirubinemia is a prognostic factor for treatment outcome in pediatric ALL and genetic variation in UGT1A aids in predicting the clinical impact of hyperbilirubinemia.
TRIAL REGISTRATION
BACKGROUND
http://www.
CLINICALTRIALS
RESULTS
gov ; #NCT00430118.
Identifiants
pubmed: 36639636
doi: 10.1186/s13046-022-02585-x
pii: 10.1186/s13046-022-02585-x
pmc: PMC9838013
doi:
Substances chimiques
Bilirubin
RFM9X3LJ49
Banques de données
ClinicalTrials.gov
['NCT00430118']
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
21Informations de copyright
© 2023. The Author(s).
Références
J Clin Pharmacol. 2016 Apr;56(4):461-73
pubmed: 26313268
Blood. 2010 Apr 22;115(16):3206-14
pubmed: 20154213
Leukemia. 2012 May;26(5):902-9
pubmed: 22076464
J Pediatr Hematol Oncol. 2010 Oct;32(7):554-63
pubmed: 20724951
Blood. 2016 Apr 28;127(17):2101-12
pubmed: 26888258
N Engl J Med. 1969 Jun 5;280(23):1266-71
pubmed: 5770050
Prog Liver Dis. 1995;13:125-50
pubmed: 9224500
J Biol Chem. 1991 Jan 15;266(2):1043-7
pubmed: 1898728
Best Pract Res Clin Gastroenterol. 2010 Oct;24(5):555-71
pubmed: 20955959
J Hepatol. 2003 Jan;38(1):107-17
pubmed: 12480568
Drug Metab Rev. 2010 Feb;42(1):168-81
pubmed: 20070246
Pediatr Blood Cancer. 2018 Mar;65(3):
pubmed: 29218844
J Clin Pharmacol. 2016 Apr;56(4):450-60
pubmed: 26637161
Pediatr Blood Cancer. 2015 Jul;62(7):1195-201
pubmed: 25855413
J Hepatol. 2009 May;50(5):1010-8
pubmed: 19303655
Yonsei Med J. 2014 Jan;55(1):232-9
pubmed: 24339312
In Vivo. 2019 Jul-Aug;33(4):1333-1339
pubmed: 31280227
Br J Cancer. 2020 Apr;122(9):1277-1287
pubmed: 32047295
Clin Pharmacol Ther. 2019 May;105(5):1095-1105
pubmed: 30447069
Leuk Lymphoma. 2015 Mar;56(3):814-6
pubmed: 25005032
Cancers (Basel). 2021 Mar 29;13(7):
pubmed: 33805415
Blood. 2013 Nov 7;122(19):3298-307
pubmed: 23996088
Nature. 2014 Jul 3;511(7507):90-3
pubmed: 24870236
J Pediatr Hematol Oncol. 2014 Oct;36(7):503-17
pubmed: 24936744
J Natl Cancer Inst. 2007 Sep 5;99(17):1290-5
pubmed: 17728214
N Engl J Med. 1995 Nov 2;333(18):1171-5
pubmed: 7565971
Hepatology. 2012 Jun;55(6):1912-21
pubmed: 22213127
Pharmacotherapy. 2017 Aug;37(8):956-972
pubmed: 28494109
Blood. 2011 Aug 25;118(8):2077-84
pubmed: 21719599
J Clin Oncol. 2015 Sep 20;33(27):2938-48
pubmed: 26304874
Clin Pharmacol Ther. 2014 Sep;96(3):324-39
pubmed: 24922307
Cancer Res. 1990 Jul 1;50(13):3921-7
pubmed: 2112982
Drug Metab Dispos. 2003 May;31(5):589-95
pubmed: 12695347
Genet Med. 2009 Jan;11(1):15-20
pubmed: 19125128
Nat Commun. 2019 Nov 25;10(1):5348
pubmed: 31767839
Lancet Oncol. 2016 Jun;17(6):e231-e239
pubmed: 27299279
Leukemia. 2010 Feb;24(2):265-84
pubmed: 20010625
Blood. 2004 Jan 1;103(1):67-72
pubmed: 12969965
Annu Rev Pharmacol Toxicol. 2000;40:581-616
pubmed: 10836148
Pharmacogenomics. 2008 Jun;9(6):703-15
pubmed: 18518849
ACS Chem Biol. 2019 Mar 15;14(3):348-355
pubmed: 30763062
Pediatr Res. 2016 Aug;80(2):252-7
pubmed: 27057738
Pharmacogenetics. 1997 Aug;7(4):255-69
pubmed: 9295054
J Exp Clin Cancer Res. 2020 Mar 5;39(1):48
pubmed: 32138788
F1000Res. 2017 Apr 7;6:444
pubmed: 28413626
Blood. 2007 May 15;109(10):4151-7
pubmed: 17264302
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8170-4
pubmed: 9653159
Eur J Cancer Clin Oncol. 1984 Jul;20(7):919-26
pubmed: 6589165